These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 339055

  • 1. Structural requirements for the metabolic activation of benzo[a]pyrene to mutagenic products: effects of modifications in the 4,5-, 7,8-, and 9,10-positions.
    Wood AW, Levin W, Lu AY, Ryan D, West SB, Yagi H, Mah HD, Jerina DM, Conney AH.
    Mol Pharmacol; 1977 Nov; 13(6):1116-25. PubMed ID: 339055
    [No Abstract] [Full Text] [Related]

  • 2. Characterization of dog hepatic drug-metabolizing enzymes and resultant effects on benzo[a]pyrene metabolite pattern and mutagenicity.
    Golan MD, Bücker M, Schmassmann HU, Raphael D, Jung R, Bindel U, Brase HO, Tegtmeyer F, Friedberg T, Lorenz J, Stasiecki P, Oesch F.
    Drug Metab Dispos; 1980 Nov; 8(3):121-6. PubMed ID: 6104571
    [No Abstract] [Full Text] [Related]

  • 3. Metabolism of benzo(a)pyrene and benzo (a)pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes.
    Wood AW, Levin W, Lu AY, Yagi H, Hernandez O, Jerina DM, Conney AH.
    J Biol Chem; 1976 Aug 25; 251(16):4882-90. PubMed ID: 821945
    [Abstract] [Full Text] [Related]

  • 4. Inhibitory effect of 3-hydroxybenzo(a)pyrene on the mutagenicity and tumorigenicity of (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene.
    Huang MT, Wood AW, Chang RL, Yagi H, Sayer JM, Jerina DM, Conney AH.
    Cancer Res; 1986 Feb 25; 46(2):558-66. PubMed ID: 3079665
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Metabolic activation of dibenzo(a,h)anthracene and its dihydrodiols to bacterial mutagens.
    Wood AW, Levin W, Thomas PE, Ryan D, Karle JM, Yagi H, Jerina DM, Conney AH.
    Cancer Res; 1978 Jul 25; 38(7):1967-73. PubMed ID: 350381
    [No Abstract] [Full Text] [Related]

  • 12. Effect of glutathione and uridine 5'-diphosphoglucuronic acid on benzo(a)pyrene mutagenesis in the Salmonella/microsome assay.
    Malaveille C, Brun G, Hautefeuille A, Bartsch H.
    Dev Toxicol Environ Sci; 1980 Jul 25; 8():175-80. PubMed ID: 6273102
    [No Abstract] [Full Text] [Related]

  • 13. Mutagenicity and cytotoxicity of benzo(a)pyrene arene oxides, phenols, quinones, and dihydrodiols in bacterial and mammalian cells.
    Wislocki PG, Wood AW, Chang RL, Levin W, Yagi H, Hernandez O, Dansette PM, Herina DM, Conney AH.
    Cancer Res; 1976 Sep 25; 36(9 pt.1):3350-7. PubMed ID: 788898
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship between benzo(a)pyrene-induced DNA base modification and frequency of reverse mutations in mutant strains of Salmonella typhimurium.
    Fahl WE, Scarpelli DG, Gill K.
    Cancer Res; 1981 Sep 25; 41(9 Pt 1):3400-6. PubMed ID: 6266655
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Species differences in activating and inactivating enzymes related to the control of mutagenic metabolites.
    Oesch F, Raphael D, Schwind H, Glatt HR.
    Arch Toxicol; 1977 Dec 30; 39(1-2):97-108. PubMed ID: 341853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.